Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01133990 · ClinicalTrials.gov registry record · Phase 1
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01133990 is a Phase 1 study that was terminated before completion, run by Eisai. The registered enrollment target is 5 participants.
The verdict
NCT01133990, a Phase 1 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.
Interventions
- DRUG Bevacizumab
- DRUG FOLFIRI
- DRUG E7820
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-03-04 |
| Est. Completion | 2011-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01133990
The ClinicalTrials.gov registry entry for NCT01133990 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01133990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01133990 about?
NCT01133990 is a clinical study titled "FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer". The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.
What is the current status of trial NCT01133990?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-03-04. Estimated completion is 2011-02-18.
What interventions are being tested in trial NCT01133990?
The interventions under investigation include: Bevacizumab (DRUG), FOLFIRI (DRUG), E7820 (DRUG).
Who is sponsoring clinical trial NCT01133990?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.